Monday, October 20, 2025 from 12:30 p.m. to 1:30 p.m. CDT at Greenway FGHIJ, 2nd Floor
This session is being recorded.
Learn MoreAvailable for 1.00 hours of CPE creditActivity Number: 0204-9999-25-246-L01-PActivity Type: An Application-Based Activity
This session is designed to provide an in-depth understanding of the current landscape of anti-amyloid medications for Alzheimer’s disease and mild cognitive impairment with an overall goal to close gaps in current practice related to the use of these medications. Promoting a more consistent, evidence-based approach to prescribing, monitoring, and patient management pharmacists can ensure the safe and effective use of these new treatments.
This activity is approved for Board Certified Geriatric Pharmacist (BCGP) recertification credit.
The BCGP Clinical Sessions are part of the professional development program for the recertification of board-certified Geriatric pharmacists by the Board of Pharmacy Specialties and jointly provided by ACCP and the American Society of Health-System Pharmacists (ASHP). In order to earn the BCGP recertification credit, participants must attend the session, claim the continuing pharmacy education credit, and pass the associated posttest. Access to the Clinical Sessions posttests will be available on December 17, 2025, at www.accp.com/myaccount to anyone who has purchased access to the BCGP posttests. For participants who have not purchased access to the posttests, access can be purchased until 1:00 p.m. on Tuesday, October 21, at the ACCP Registration Desk. The deadline to submit posttests for these sessions will be December 15, 2026.
Learning Objectives1. Identify appropriate patient populations for anti-amyloid medications based on clinical criteria, biomarkers, and disease stage.
2. Explain the mechanisms, efficacy, and safety profile of anti-amyloid therapies, including potential adverse effects and monitoring requirements.
3. Assess the understanding of interprofessional roles in managing patients receiving anti-amyloid treatment, focusing on collaboration between pharmacists, nurses, and physicians.
4. Apply evidence-based clinical guidelines to make informed decisions on the initiation, monitoring, and management of anti-amyloid medications for Alzheimer’s and mild cognitive impairment (MCI) patients.
 | | Speaker: | Jennifer Pruskowski, Pharm.D., BCPS | | Assistant Professor and Director of Geriatric Pharmacy Research and Education
University of Pittsburgh School of Medicine, Division of Geriatric Medicine;
Associate Director for Education and Evaluation
VA Pittsburgh Geriatric Research Education and Clinical Center
Pittsburgh, Pennsylvania
| | View Biography |
|